- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Innovating IBD Treatment Using Behavioral Health Tactics
Gastropsychiatrist Eva Szigethy, MD, PhD, and Benjamin Cohen, MD, Cleveland Clinic, discuss quality of life improvement in terms of behavioral health and inflammatory bowel disease (IBD).
The University of Pittsburgh Medical Center (UPMC) Specialty Medical Home (SMH) model is redefining care for patients with inflammatory bowel disease (IBD) and behavioral health conditions by delivering integrated, patient-centered, team-based support.1 Three pioneering SMH clinics at the University of Pittsburgh Medical Center (UPMC), Cleveland Clinic, and Mount Sinai Hospital are addressing the physical and psychological complexity of IBD through coordinated care that includes medical, nutritional, and behavioral health services.
At the heart of this initiative is the UPMC Center for High-Value Health Care, which served as the primary recipient of a Patient-Centered Outcomes Research Institute (PCORI®) grant (IHS-2017C3-8930) to lead and implement this innovative care model.
Eva Szigethy, MD, PhD, a child and adult psychiatrist specializing in gastropsychiatry, served as the clinical lead within the UPMC IBD Medical Home. She emphasized that integrating behavioral health care reduces stigma, promotes patient engagement, and empowers individuals to become active participants in managing their chronic illness.
Benjamin Cohen, MD, co-section head and clinical director for IBD at the Cleveland Clinic, participated as a co-investigator in the PCORI-funded study. He pointed to the growing complexity of IBD treatments and reduced access to gastroenterology visits as clear drivers for adopting a multidisciplinary SMH model. This model improves care continuity, facilitates shared decision-making, and enhances quality of life by addressing the interplay between brain and gut health.
Reference
1. Specialty medical homes to improve outcomes for patients with inflammatory bowel disease and behavioral health conditions. UPMC. February 1, 2019. Accessed May 23, 2025. https://www.upmchighvaluehealthcare.com/our-work/research-evaluation-and-stakeholder-engagement/specialty-medical-homes-to-improve-outcomes-for-patients-with-inflammatory-bowel-disease-and-behavioral-health-conditions/
FUNDING ACKNOWLEDGEMENT: This work was (partially) supported through a Patient-Centered Outcomes Research Institute (PCORI) Award (IHS-2017C3-8930).
DISCLAIMER: All statements in this newsletter, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or Methodology Committee.
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
